Skip to main content
Erschienen in: Acta Diabetologica 4/2013

01.08.2013 | Original Article

Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy

verfasst von: Ahmed M. Abu El-Asrar, Mohd Imtiaz Nawaz, Dustan Kangave, Mohammed Miraj Siddiquei, Mohammad Shamsul Ola, Ghislain Opdenakker

Erschienen in: Acta Diabetologica | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

We determined the levels of the endogenous angiogenesis inhibitors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), thrombospondin (TSP)-1 and TSP-2 in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and correlated their levels with clinical disease activity and the levels of vascular endothelial growth factor (VEGF). Vitreous samples from 30 PDR and 25 nondiabetic patients were studied by enzyme-linked immunosorbent assay. TSP-1 was not detected. VEGF and TSP-2 levels were significantly higher in PDR with active neovascularization compared with inactive PDR and nondiabetic patients (P < 0.001 for both comparisons). VEGF, sVEGFR-1 and TSP-2 levels were significantly higher in PDR with hemorrhage compared with PDR without hemorrhage and nondiabetic patients (P = 0.0063; 0.0144; <0.001, respectively). VEGF and sVEGFR-1 levels were significantly higher in PDR without traction retinal detachment (TRD) compared with PDR with TRD and nondiabetic patients (P = 0.038; 0.022, respectively). TSP-2 levels were significantly higher in PDR with TRD compared with PDR without TRD and nondiabetic patients (P < 0.001). There was a significant correlation between levels of VEGF and sVEGFR-1 (r = 0.427, P = 0.038). Our findings suggest that upregulation of sVEGFR-1 and TSP-2 may be a protective mechanism against progression of angiogenesis associated with PDR. TSP-2 might be associated with TRD.
Literatur
1.
Zurück zum Zitat Spranger J, Pfeiffer AP (2001) New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109:S438–S450PubMedCrossRef Spranger J, Pfeiffer AP (2001) New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109:S438–S450PubMedCrossRef
2.
Zurück zum Zitat Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef
3.
Zurück zum Zitat Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H (2008) Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 115:1916–1922PubMedCrossRef Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H (2008) Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 115:1916–1922PubMedCrossRef
4.
Zurück zum Zitat Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMedCrossRef Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMedCrossRef
5.
Zurück zum Zitat Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS (2010) A system biology perspective on sVEGFR-1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14:528–552PubMed Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS (2010) A system biology perspective on sVEGFR-1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14:528–552PubMed
6.
Zurück zum Zitat Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90–99PubMedCrossRef Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90–99PubMedCrossRef
7.
Zurück zum Zitat Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid in patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid in patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef
8.
Zurück zum Zitat Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A, Kovesdi I, Balestrazzi E, Abeni DC, Ali RR, Capogrossi MC (2004) Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6:992–1002PubMedCrossRef Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A, Kovesdi I, Balestrazzi E, Abeni DC, Ali RR, Capogrossi MC (2004) Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6:992–1002PubMedCrossRef
9.
Zurück zum Zitat Kyriakides TR, Tam JW (1999) Bornstein. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787PubMedCrossRef Kyriakides TR, Tam JW (1999) Bornstein. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787PubMedCrossRef
10.
Zurück zum Zitat Lin T-N, Kim G-M, Chen J-J, Cheung W-M, He YY, Hsu CY (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34:177–186PubMedCrossRef Lin T-N, Kim G-M, Chen J-J, Cheung W-M, He YY, Hsu CY (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34:177–186PubMedCrossRef
11.
Zurück zum Zitat Hawighorst T, Velasco P, Streit M, Hong Y-K, Kyriakides TR, Brown LF, Bornstein P, Detmar M (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640PubMedCrossRef Hawighorst T, Velasco P, Streit M, Hong Y-K, Kyriakides TR, Brown LF, Bornstein P, Detmar M (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640PubMedCrossRef
12.
Zurück zum Zitat Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96:14888–14893PubMedCrossRef Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96:14888–14893PubMedCrossRef
13.
Zurück zum Zitat Noh Y-H, Matsuda K, Hong Y-K, Kunstfeld R, Riccardi L, Koch M, Oura H, Dadras SS, Streit M, Detmar M (2003) An N-terminal 80 kDa recombinant fragment of human thrombopsondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121:1536–1543PubMedCrossRef Noh Y-H, Matsuda K, Hong Y-K, Kunstfeld R, Riccardi L, Koch M, Oura H, Dadras SS, Streit M, Detmar M (2003) An N-terminal 80 kDa recombinant fragment of human thrombopsondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121:1536–1543PubMedCrossRef
14.
Zurück zum Zitat Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, Hawighorst T (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128:337–346PubMedCrossRef Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, Hawighorst T (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128:337–346PubMedCrossRef
15.
Zurück zum Zitat MacLauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR (2009) Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9 and soluble VEGF. J Histochem Cytochem 57:301–313PubMedCrossRef MacLauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR (2009) Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9 and soluble VEGF. J Histochem Cytochem 57:301–313PubMedCrossRef
16.
Zurück zum Zitat Kyriakides TR, Zhu Y-H, Yang Z, Huynh G, Bornstein P (2001) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255–1262PubMedCrossRef Kyriakides TR, Zhu Y-H, Yang Z, Huynh G, Bornstein P (2001) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255–1262PubMedCrossRef
17.
Zurück zum Zitat Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, Bornstein P, Sessa WC, Kyriakides TR (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173:879–891PubMedCrossRef Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, Bornstein P, Sessa WC, Kyriakides TR (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173:879–891PubMedCrossRef
18.
Zurück zum Zitat Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087–2098PubMedCrossRef Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087–2098PubMedCrossRef
19.
Zurück zum Zitat Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893–1905PubMedCrossRef Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893–1905PubMedCrossRef
20.
Zurück zum Zitat Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34PubMedCrossRef Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34PubMedCrossRef
21.
Zurück zum Zitat Adri VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-Free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267CrossRef Adri VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-Free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267CrossRef
22.
Zurück zum Zitat Bergers G, Prekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Natl Cell Biol 2:737–744CrossRef Bergers G, Prekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Natl Cell Biol 2:737–744CrossRef
23.
Zurück zum Zitat Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691PubMedCrossRef Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691PubMedCrossRef
24.
Zurück zum Zitat Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J (2006) Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 17:155–165PubMed Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J (2006) Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 17:155–165PubMed
25.
Zurück zum Zitat Ogata N, Ando A, Uyama M, Matsumura M (2001) Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Exp Ophthalmol 239:87–95CrossRef Ogata N, Ando A, Uyama M, Matsumura M (2001) Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Exp Ophthalmol 239:87–95CrossRef
26.
Zurück zum Zitat Xiao M, McLeod D, Cranley J, Williams G, Boulton M (1999) Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol 83:728–736PubMedCrossRef Xiao M, McLeod D, Cranley J, Williams G, Boulton M (1999) Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol 83:728–736PubMedCrossRef
Metadaten
Titel
Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy
verfasst von
Ahmed M. Abu El-Asrar
Mohd Imtiaz Nawaz
Dustan Kangave
Mohammed Miraj Siddiquei
Mohammad Shamsul Ola
Ghislain Opdenakker
Publikationsdatum
01.08.2013
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 4/2013
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0330-9

Weitere Artikel der Ausgabe 4/2013

Acta Diabetologica 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.